XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative Effect, Period of Adoption, Adjustment
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2020     34,481          
Beginning Balance at Dec. 31, 2020 $ 1,400,181   $ 345 $ 0   $ 1,506,271   $ (106,435)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 64,496         64,496    
Other comprehensive income (loss):                
Cumulative translation adjustment (5,242)             (5,242)
Issuance of common stock in connection with:                
Exercise of options (in shares)     12          
Exercise of options 434     434        
Restricted share grants (in shares)     157          
Restricted share grants (7,231)   $ 1 (7,232)        
Stock units issued under incentive compensation plan 2,603     2,603        
Purchase and retirement of common stock (in shares)     (422)          
Purchase and retirement of common stock (46,133)   $ (4) (3,047)   (43,082)    
Share-based compensation 7,242     7,242        
Ending Balance (in shares) at Mar. 31, 2021     34,228          
Ending Balance at Mar. 31, 2021 1,416,350   $ 342 0   1,527,685   (111,677)
Beginning Balance (in shares) at Dec. 31, 2020     34,481          
Beginning Balance at Dec. 31, 2020 1,400,181   $ 345 0   1,506,271   (106,435)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 196,758              
Other comprehensive income (loss):                
Cumulative translation adjustment (18,042)              
Issuance of common stock in connection with:                
Stock units issued under incentive compensation plan 2,603              
Ending Balance (in shares) at Sep. 30, 2021     34,295          
Ending Balance at Sep. 30, 2021 1,544,303   $ 343 8,490   1,659,947   (124,477)
Beginning Balance (in shares) at Mar. 31, 2021     34,228          
Beginning Balance at Mar. 31, 2021 1,416,350   $ 342 0   1,527,685   (111,677)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 62,782         62,782    
Other comprehensive income (loss):                
Cumulative translation adjustment 5,807             5,807
Issuance of common stock in connection with:                
Exercise of options (in shares)     33          
Exercise of options 1,137   $ 1 1,136        
Restricted share grants (in shares)     21          
Restricted share grants (1,814)     (1,814)        
Share-based compensation 4,948     4,948        
Ending Balance (in shares) at Jun. 30, 2021     34,282          
Ending Balance at Jun. 30, 2021 1,489,210   $ 343 4,270   1,590,467   (105,870)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 69,480         69,480    
Other comprehensive income (loss):                
Cumulative translation adjustment (18,607)             (18,607)
Issuance of common stock in connection with:                
Exercise of options (in shares)     4          
Exercise of options 126     126        
Restricted share grants (in shares)     9          
Restricted share grants (866)     (866)        
Share-based compensation 4,960     4,960        
Ending Balance (in shares) at Sep. 30, 2021     34,295          
Ending Balance at Sep. 30, 2021 $ 1,544,303   $ 343 8,490   1,659,947   (124,477)
Beginning Balance (in shares) at Dec. 31, 2021 34,333   34,333          
Beginning Balance at Dec. 31, 2021 $ 1,583,321 $ (12,053) $ 343 13,662 $ (34,131) 1,698,156 $ 22,078 (128,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 59,321         59,321    
Other comprehensive income (loss):                
Cumulative translation adjustment (6,191)             (6,191)
Issuance of common stock in connection with:                
Exercise of options (in shares)     26          
Exercise of options 923     923        
Restricted share grants (in shares)     134          
Restricted share grants (7,834)   $ 2 (7,836)        
Stock units issued under incentive compensation plan 1,664     1,664        
Purchase and retirement of common stock (in shares)     (22)          
Purchase and retirement of common stock (3,098)     (3,098)        
Conversion of convertible senior notes due 2023 (2)     (2)        
Share-based compensation 5,967     5,967        
Reclassification of negative additional paid-in capital 0     22,851   (22,851)    
Ending Balance (in shares) at Mar. 31, 2022     34,471          
Ending Balance at Mar. 31, 2022 $ 1,622,018   $ 345 0   1,756,704   (135,031)
Beginning Balance (in shares) at Dec. 31, 2021 34,333   34,333          
Beginning Balance at Dec. 31, 2021 $ 1,583,321 $ (12,053) $ 343 13,662 $ (34,131) 1,698,156 $ 22,078 (128,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 188,016              
Other comprehensive income (loss):                
Cumulative translation adjustment (95,345)              
Issuance of common stock in connection with:                
Stock units issued under incentive compensation plan $ 1,664              
Ending Balance (in shares) at Sep. 30, 2022 34,422   34,422          
Ending Balance at Sep. 30, 2022 $ 1,644,583   $ 344 0   1,868,424   (224,185)
Beginning Balance (in shares) at Mar. 31, 2022     34,471          
Beginning Balance at Mar. 31, 2022 1,622,018   $ 345 0   1,756,704   (135,031)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 51,428         51,428    
Other comprehensive income (loss):                
Cumulative translation adjustment (40,679)             (40,679)
Issuance of common stock in connection with:                
Exercise of options (in shares)     22          
Exercise of options 687     687        
Restricted share grants (in shares)     47          
Restricted share grants (8,907)     (8,907)        
Conversion of convertible senior notes due 2023 (11)     (11)        
Share-based compensation 6,083     6,083        
Reclassification of negative additional paid-in capital 0     2,647   (2,647)    
Ending Balance (in shares) at Jun. 30, 2022     34,540          
Ending Balance at Jun. 30, 2022 1,630,619   $ 345 499   1,805,485   (175,710)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 77,267         77,267    
Other comprehensive income (loss):                
Cumulative translation adjustment (48,475)             (48,475)
Issuance of common stock in connection with:                
Restricted share grants (in shares)     10          
Restricted share grants (837)     (837)        
Purchase and retirement of common stock (in shares)     (128)          
Purchase and retirement of common stock (20,432)   $ (1) (20,431)        
Share-based compensation 6,441     6,441        
Reclassification of negative additional paid-in capital $ 0     14,328   (14,328)    
Ending Balance (in shares) at Sep. 30, 2022 34,422   34,422          
Ending Balance at Sep. 30, 2022 $ 1,644,583   $ 344 $ 0   $ 1,868,424   $ (224,185)